Navigation Links
Relmada Therapeutics To Present At LD MICRO Conference
Date:11/24/2014

NEW YORK, Nov. 24, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, is scheduled to present at the LD MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December 3, 2014.  The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in Los Angeles, California.

The presentation is scheduled for 8:30 a.m. PST/11:30 a.m. EST and will be available as a live and archived webcast. The replay will be available for 90 days following the live broadcast.  Interested parties may access the webcast from the Relmada website, http://www.relmada.com.

Mr. Traversa and other members of the management team will be available for one-on-one meetings at the conference.  Members of the investment community who are interested in meeting with management should contact Michael Becker, senior vice president of finance and corporate development at Relmada Therapeutics, Inc., via telephone at (212) 702-7169 or e-mail at mbecker@relmada.com.

About LD MICRO

LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space.  Since 2002, the firm has published reports on select companies throughout the year.  The firm hosts the LD MICRO "Main Event" Micro-Cap Growth Conference for investors in December of each year.  This year's conference will feature presentations by over 240 publicly traded companies and is expected to attract more than 1,000 attendees. For additional information, please visit the LD Micro conference website at http://www.ldmicro.com.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain.  The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine.  The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.  For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Relmada Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
2. Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
3. Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
4. Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
5. Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone
6. Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company
7. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
8. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
9. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
10. Relmada Therapeutics Announces LevoCap ER Development Progress
11. PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Councils 2014 Legend of Technology Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2019)... ... November 06, 2019 , ... Big Buzz continues to build upon ... into healthcare and medical technology. The agency - which primarily serves the biosciences, specialty ... members spoke at prominent events nationwide. , In June, Big Buzz was named a ...
(Date:11/6/2019)... ... November 06, 2019 , ... James M. Barthel, CEO ... most lucrative way to transform their range lead into profit by giving the range ... quickly receive a check for the absolute highest value for their lead. No one ...
(Date:11/6/2019)... N.Y. (PRWEB) , ... November 06, 2019 , ... ... CEO of LiveOnNY, presented Northern Westchester Hospital (NWH) President and CEO, Joel Seligman, ... Seligman was honored for his commitment to raising awareness, providing education and registering ...
Breaking Medicine Technology:
(Date:11/12/2019)... Calif. (PRWEB) , ... November 12, 2019 , ... ... the most complete business management solution for physical therapy and rehabilitation operators throughout ... patient engagement technology with customers in 102 countries, today announces a joint venture ...
(Date:11/11/2019)... ... November 11, 2019 , ... ... to dental groups in the United States, today announced the grand opening of ... CA. , Patients will enjoy convenient hours, comfortable offices and full-service care at ...
(Date:11/11/2019)... ... 2019 , ... Artemis, the leading enterprise Cultivation ... adoption of compliance technology in the wake of the November 3 voluntary ... in the United States and Canada due to potential contamination with Listeria monocytogenes. ...
(Date:11/9/2019)... ... 2019 , ... Pennsylvania College of Health Sciences, the area’s ... the fourth quarter of the 2018-2019 academic year, the school’s NCLEX scores continue ... College’s annual pass rate for the 2018-2019 academic year was 95.02%, maintaining the ...
(Date:11/7/2019)... ... 06, 2019 , ... An October 13 article on Yahoo News ... the article, while no U.S. state had an obesity rate above 15 percent in ... The article cites quite a few reasons for this rise, including eating out more ...
Breaking Medicine News(10 mins):